Aclaris Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
0.00%
vs ±33.1% implied · ×0.00
shaded = implied · ▲▼ = realized
Aclaris Therapeutics has 1 disclosed supplier and 4 disclosed customers in SEC filings.
SentenceIn November 2024, we entered into an exclusive license agreement (the "Biosion Agreement") with Biosion, Inc. ("Biosion") pursuant to which we received the exclusive rights to develop, manufacture and commercialize bosakitug (ATI-045) and ATI-052 worldwide, excluding Mainland China, Macau, Hong Kong and Taiwan ("Greater China").
ACRS 10-Kaccession 0001104659-26-020540
SentenceIn October 2019, we sold RHOFADE (oxymetazoline hydrochloride) cream, 1% ("RHOFADE"), to EPI Health, LLC ("EPI Health") pursuant to an asset purchase agreement.
ACRS 10-Kaccession 0001104659-26-020540
SentenceIn November 2022, we entered into a license agreement with Pediatrix Therapeutics, Inc. ("Pediatrix") under which we granted Pediatrix the exclusive rights to develop, manufacture and commercialize lepzacitinib in Greater China.
ACRS 10-Kaccession 0001104659-26-020540
SentenceIn December 2023, we entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. ("Sun Pharma").
ACRS 10-Kaccession 0001104659-26-020540
Aclaris Therapeutics, Inc.
3.98
−0.01 · −0.35%
post 3.98 0.00%
Linked news
NewsExpected move
Inputsspot 3.97exp Mar 19ATM strike 4ATM straddle 1.82IV 95%